<DOC>
	<DOC>NCT01178346</DOC>
	<brief_summary>The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.</brief_summary>
	<brief_title>Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who are eligible for randomization or have not reached Week 12 in Nabi4514 or Nabi4515 studies. Subjects who agree to participate in healthrelated quality of life study. Subjects who are unable to complete a HRQoL questionnaire because of inability to understand the language or due to mental impairment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pharmacoeconomic</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Health Outcomes</keyword>
	<keyword>Smoking</keyword>
	<keyword>NicVAX</keyword>
	<keyword>Smoking vaccine</keyword>
	<keyword>Smoking cessation</keyword>
</DOC>